DMAC May 2024 5.000 call
| Previous Close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 0.7500 |
| Strike | 5.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.0500 - 0.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 42 |
Insider MonkeyDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call Transcript May 11, 2024 DiaMedica Therapeutics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2024 Conference Call. An […]
Business WireDiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
MINNEAPOLIS, May 08, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended March 31, 2024. Management will host a conference call Thursday, May 9, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and first quarter 2024 financial results.
- Business Wire
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
MINNEAPOLIS, May 02, 2024--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2024 financial results will be released after the markets close on Wednesday, May 8th. DiaMedica will host a live conference call on Thursday, May 9th at 7:00 AM Central Time to provide a business update and discuss financial results.
